Try our Advanced Search for more refined results
CHAIRES et al v. NOVO NORDISK INC. et al
Case Number:
2:17-cv-00699
Court:
Nature of Suit:
Racketeer/Corrupt Organization
Judge:
Firms
- Alston & Bird
- Barnes & Thornburg
- Carella Byrne
- Chiesa Shahinian
- Cicala Law Firm
- Cohn Lifland
- Covington & Burling
- Critchley Kinum
- Forman Watkins
- Genova Burns
- Gibbons PC
- Kessler Topaz
- Lite DePalma
- Marino Tortorella
- McCarter & English
- McElroy Deutsch
- Miller Shah LLP
- O'Toole Scrivo
- Reed Smith
- Robbins Geller
- Walsh Pizzi
- Weitz & Luxenberg
Companies
- CVS Health Corp.
- Eli Lilly & Co.
- Express Scripts Holding Co.
- Novo Nordisk A S
- Optum Inc.
- OptumRx Inc.
- Rochester Drug Cooperative Inc.
- Sanofi
- UnitedHealth Group Inc.
Government Agencies
Sectors & Industries:
-
April 23, 2024
Failure Of Eli Lilly Insulin Deal Won't End Patients' Litigation
The collapse of a massive deal to settle claims Eli Lilly illegally inflated insulin prices may not alter the trajectory of the underlying litigation, as patients are already pressing ahead with a new version of their proposed class action.
-
April 16, 2024
Eli Lilly's Insulin Price Cap Deal Collapses After Cert. Denial
Eli Lilly & Co. and insulin buyers have called off a proposed nationwide settlement that would've capped insulin prices and been worth up to $500 million over several years, a decision that was made after the buyers lost a class certification bid early this year, according to the buyers' counsel.
-
May 26, 2023
Lilly To Pay $13M, Cap Insulin Cost In Deal Worth Up To $500M
Insulin buyers asked a New Jersey federal judge Friday to greenlight a class settlement with Eli Lilly & Co. resolving claims it schemed to drive up insulin drug prices, a deal that includes $13.5 million cash and insulin price caps which plaintiffs' lawyers value at $500 million over four years.